abatacept	TNF-alpha treatment	Juvenile Idiopathic Arthritis (JIA) - proportion of patients relapsed after stopping the treatment	14358	14709	Studies that investigated the efficacy of abatacept in JIA have identified a similar proportion of patients achieving ACR30 Pediatric as with anti-TNF-alpha [34-36]. Compared with TNF-alpha treatment, the onset of action abatacept was delayed; it took a longer time to relapse and a smaller proportion of patients relapsed after stopping the treatment
abatacept	tocilizumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	11446	11577	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
abatacept	TNF-alpha treatment	Juvenile Idiopathic Arthritis (JIA) - proportion of patients relapsed after stopping the treatment	14524	14709	Compared with TNF-alpha treatment, the onset of action abatacept was delayed; it took a longer time to relapse and a smaller proportion of patients relapsed after stopping the treatment
abatacept	tocilizumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	11446	11576	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab
abatacept	TNF-alpha treatment	Juvenile Idiopathic Arthritis (JIA) - time to relapse	14524	14709	Compared with TNF-alpha treatment, the onset of action abatacept was delayed; it took a longer time to relapse and a smaller proportion of patients relapsed after stopping the treatment
 abatacept	adalimumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	11446	11577	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
